Policy, Schedule and Vaccine Product Choice: Q&A Session

The Q&A session highlighted critical considerations for transitioning to single-dose HPV vaccination, including evidence needs for NITAG decision-making, updates on ongoing trials like HANDS, and the unique immunological advantages of virus-like particle vaccines. Participants raised concerns about vaccine efficacy in older adolescents, genotype distribution differences (e.g., HPV 52 prevalence), and implications for vaccine selection. Discussions […]

Decision-making to switch to single dose

The presentation outlines Myanmar’s policy shift from a two-dose to a single-dose HPV vaccination schedule, driven by operational challenges during COVID-19, missed cohorts, and WHO’s updated recommendations. NITAG adopted a systematic, evidence-based approach using PICO criteria to guide decision-making, ensuring transparency and technical rigor. The revised strategy targets 9–11-year-old girls through school and community campaigns, […]

>